Abstract 2166
Background
Patients (pts) with advanced CCOC have a significantly poorer prognosis than other Epithelial ovarian cancer (EOC) subtypes. Being able to predict which pts are more likely to relapse could assist with treatment and monitoring decisions. The system inflammatory score (SIS) aims to predict postsurgical prognosis for CCOC by stratifying pts into 3 groups (gps). The Risk of OVarian cAncer Relpase (ROVAR) score aims to predict ROR for EOC following first line treatment and stratifies pts into low/intermediate (int)/high gps. We attempted to validate both scores in a non-trial population.
Methods
We reviewed the medical records for pts with CCOC treated at two UK gynaecological cancer centres between 2002 and 2017. Data comprising pt and tumor characteristics, treatment and outcome. Analysis was performed using Mantel Cox and Fisher Exact Tests.
Results
119 pts; stage I (65), II (19), III (22), IV (10) and unknown (3). ROVAR was calculated for 90 (75%) pts; 24 (20%) had incomplete data, 6 (5%) excluded for other. Pts classified into low (20%), int (44%) and high (36%) gps. ROR for low or int gps vs high p = 0.0001; ROR for low vs int gps p = 1. Compared to low/int, pts in high-risk gp were younger 53.87yrs (34-72) vs 57.81yrs (35-74), had smaller tumours 106mm (45-240) vs 136mm (50-230), with increase in both hypercalcaemia (21% vs 5%; p = 0.306) and thromboembolic events (37.5% vs 10%; p = 0.0047). SIS was calculated for 67 pts (56%); 39 (33%) had insufficient data, 13 (11%) excluded for other. Pts classified into gp 0 (34.3%), 1 (37.3%) and 2 (28.3%) with no statistical difference in PFS (p = 0.9118) or OS (p = 0.849) between gps.
Conclusions
ROVAR significantly predicts ROR in CCOC in pts with high vs low/int risk disease. Our data suggests that the features that promote treatment-resistance are linked to paraneoplastic phenomenon and emerge early in tumour development, resulting in diagnosis at a smaller size in younger women. Another possibility is that these are two pathologically similar, but ultimately distinct, disease entities from the outset. Patients with high risk disease may benefit from more intensive follow-up and, given the chemo-resistant phenotype of the disease, early enrolment in clinical trials.
Clinical trial identification
Legal entity responsible for the study
Michael-John Devlin.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract